(ALTS) ALT5 Sigma - Overview
Stock: Trading, Payment, Tokenization, Nitrite, Naltrexone
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 151% |
| Relative Tail Risk | -17.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.37 |
| Alpha | -94.65 |
| Character TTM | |
|---|---|
| Beta | 1.526 |
| Beta Downside | 1.249 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.28% |
| CAGR/Max DD | 0.00 |
Description: ALTS ALT5 Sigma January 26, 2026
ALT5 Sigma Corporation (NASDAQ: ALTS) is a Las Vegas-based firm that combines blockchain-enabled fintech services with a nascent biotech pipeline. Through its Fintech segment it offers the ALT 5 Prime OTC digital-asset trading platform and the ALT 5 Pay crypto-payment gateway, while its Biotechnology segment focuses on non-opioid pain-and-addiction therapies, notably JAN 101 (sodium nitrite) and JAN 123 (low-dose naltrexone). The company rebranded from JanOne Inc. in July 2024 and now reports under the GICS sub-industry “Pharmaceuticals.”
As of the most recent quarterly filing (Q1 2024), ALT5’s market capitalization hovered around **$48 million**, with **$0.12 share price** and a cash balance of **$12 million**. The fintech arm reported **$3.2 million** in gross transaction volume for ALT 5 Prime in Q1, reflecting a **45 % YoY increase** driven by higher institutional crypto-trading activity (global crypto-exchange volume grew ~5 % YoY in 2023). On the biotech side, JAN 101 completed its Phase 2a trial in August 2023, achieving its primary endpoint with a **30 % reduction in claudication distance** among peripheral arterial disease patients; however, the company has yet to generate revenue from this pipeline, and further clinical milestones remain uncertain. Overall sector trends show U.S. pharmaceutical R&D spending up **7 % YoY** and blockchain-based payment solutions gaining traction as merchants seek to capture the estimated **$2 trillion** crypto-asset market.
Given the dual-track model and early-stage revenue profile, investors should closely monitor upcoming Phase 2b data for JAN 101 and the scaling of ALT 5 Prime’s transaction volume before forming a view on sustainable earnings. For a deeper dive into ALT5’s valuation metrics, the ValueRay platform offers a transparent, data-driven analysis.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 33.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -5.50 > 1.0 |
| NWC/Revenue: -46.56% < 20% (prev -146.7%; Δ 100.1% < -1%) |
| CFO/TA -0.01 > 3% & CFO -17.4m > Net Income 33.1m |
| Net Debt (10.5m) to EBITDA (56.4m): 0.19 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (168.7m) vs 12m ago 1217 % < -2% |
| Gross Margin: 39.87% > 18% (prev 0.49%; Δ 3939 % > 0.5%) |
| Asset Turnover: 2.90% > 50% (prev 9.49%; Δ -6.59% > 0%) |
| Interest Coverage Ratio: 17.66 > 6 (EBITDA TTM 56.4m / Interest Expense TTM 2.99m) |
Altman Z'' 0.15
| A: -0.01 (Total Current Assets 44.8m - Total Current Liabilities 56.4m) / Total Assets 1.64b |
| B: -0.01 (Retained Earnings -19.9m / Total Assets 1.64b) |
| C: 0.06 (EBIT TTM 52.8m / Avg Total Assets 857.5m) |
| D: -0.17 (Book Value of Equity -14.6m / Total Liabilities 83.9m) |
| Altman-Z'' Score: 0.15 = B |
Beneish M -1.07
| DSRI: 0.38 (Receivables 28.8m/21.8m, Revenue 24.9m/7.11m) |
| GMI: 1.22 (GM 39.87% / 48.65%) |
| AQI: 1.75 (AQ_t 0.97 / AQ_t-1 0.56) |
| SGI: 3.50 (Revenue 24.9m / 7.11m) |
| TATA: 0.03 (NI 33.1m - CFO -17.4m) / TA 1.64b) |
| Beneish M-Score: -1.07 (Cap -4..+1) = D |
What is the price of ALTS shares?
Over the past week, the price has changed by -19.05%, over one month by +10.39%, over three months by -12.82% and over the past year by -72.22%.
Is ALTS a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALTS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18 | 958.8% |
| Analysts Target Price | 18 | 958.8% |
| ValueRay Target Price | 1.5 | -10% |
ALTS Fundamental Data Overview February 02, 2026
P/B = 0.1767
Revenue TTM = 24.9m USD
EBIT TTM = 52.8m USD
EBITDA TTM = 56.4m USD
Long Term Debt = 8.65m USD (from longTermDebt, last quarter)
Short Term Debt = 9.04m USD (from shortTermDebt, last quarter)
Debt = 17.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.5m USD (from netDebt column, last quarter)
Enterprise Value = 249.1m USD (238.6m + Debt 17.8m - CCE 7.32m)
Interest Coverage Ratio = 17.66 (Ebit TTM 52.8m / Interest Expense TTM 2.99m)
EV/FCF = -14.30x (Enterprise Value 249.1m / FCF TTM -17.4m)
FCF Yield = -6.99% (FCF TTM -17.4m / Enterprise Value 249.1m)
FCF Margin = -69.98% (FCF TTM -17.4m / Revenue TTM 24.9m)
Net Margin = 133.1% (Net Income TTM 33.1m / Revenue TTM 24.9m)
Gross Margin = 39.87% ((Revenue TTM 24.9m - Cost of Revenue TTM 15.0m) / Revenue TTM)
Gross Margin QoQ = 22.75% (prev 43.51%)
Tobins Q-Ratio = 0.15 (Enterprise Value 249.1m / Total Assets 1.64b)
Interest Expense / Debt = 4.71% (Interest Expense 839.0k / Debt 17.8m)
Taxrate = 20.57% (12.1m / 58.7m)
NOPAT = 42.0m (EBIT 52.8m * (1 - 20.57%))
Current Ratio = 0.79 (Total Current Assets 44.8m / Total Current Liabilities 56.4m)
Debt / Equity = 0.01 (Debt 17.8m / totalStockholderEquity, last quarter 1.55b)
Debt / EBITDA = 0.19 (Net Debt 10.5m / EBITDA 56.4m)
Debt / FCF = -0.60 (negative FCF - burning cash) (Net Debt 10.5m / FCF TTM -17.4m)
Total Stockholder Equity = 405.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.86% (Net Income 33.1m / Total Assets 1.64b)
RoE = 8.17% (Net Income TTM 33.1m / Total Stockholder Equity 405.4m)
RoCE = 12.76% (EBIT 52.8m / Capital Employed (Equity 405.4m + L.T.Debt 8.65m))
RoIC = 10.25% (NOPAT 42.0m / Invested Capital 409.3m)
WACC = 11.00% (E(238.6m)/V(256.5m) * Re(11.54%) + D(17.8m)/V(256.5m) * Rd(4.71%) * (1-Tc(0.21)))
Discount Rate = 11.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 460.1%
Fair Price DCF = unknown (Cash Flow -17.4m)
EPS Correlation: -34.86 | EPS CAGR: -2.56% | SUE: N/A | # QB: 0
Revenue Correlation: 92.62 | Revenue CAGR: 297.5% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-0.60 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+41.8% | Growth Revenue=+66.9%